NASDAQ:ADMA - ADMA Biologics Stock Price, Forecast & News

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

ADMA Biologics Inc (NASDAQ:ADMA) issued its quarterly earnings data on Wednesday, November, 6th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.23) by $0.04. The biotechnology company earned $7.22 million during the quarter, compared to analysts' expectations of $5.71 million. ADMA Biologics had a negative return on equity of 203.21% and a negative net margin of 260.92%. View ADMA Biologics' Earnings History.

ADMA Biologics is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for ADMA Biologics.

ADMA Biologics updated its FY 2019 Pre-Market earnings guidance on Thursday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $29.2-29.2 million, compared to the consensus revenue estimate of $25.38 million.

6 brokers have issued 1-year price targets for ADMA Biologics' stock. Their forecasts range from $4.00 to $14.00. On average, they anticipate ADMA Biologics' stock price to reach $10.20 in the next year. This suggests a possible upside of 142.9% from the stock's current price. View Analyst Price Targets for ADMA Biologics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ADMA Biologics.

Press coverage about ADMA stock has been trending somewhat negative on Friday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. ADMA Biologics earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for ADMA Biologics.

ADMA Biologics saw a increase in short interest in December. As of December 13th, there was short interest totalling 5,110,000 shares, an increase of 10.1% from the November 28th total of 4,640,000 shares. Based on an average trading volume of 708,300 shares, the short-interest ratio is presently 7.2 days. Currently, 11.3% of the shares of the stock are sold short. View ADMA Biologics' Current Options Chain.

Some companies that are related to ADMA Biologics include DBV TECHNOLOGIE/S (DBVT), NanoString Technologies (NSTG), Aerie Pharmaceuticals (AERI), Mesoblast (MESO), Krystal Biotech (KRYS), Sangamo Therapeutics (SGMO), BAVARIAN NORDIC/S (BVNRY), Proteon Therapeutics (PRTO), Atara Biotherapeutics (ATRA), AVITA MED LTD/S (RCEL), GENFIT S A/ADR (GNFT), Twist Bioscience (TWST), Vericel (VCEL), Cellectis (CLLS) and Adverum Biotechnologies (ADVM).

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Viking Therapeutics (VKTX), Corbus Pharmaceuticals (CRBP), Verastem (VSTM), Gilead Sciences (GILD), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL), Adamis Pharmaceuticals (ADMP), Bellicum Pharmaceuticals (BLCM), Catalyst Pharmaceuticals (CPRX) and Sorrento Therapeutics (SRNE).

Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADMA stock can currently be purchased for approximately $4.20.

ADMA Biologics has a market capitalization of $249.14 million and generates $16.99 million in revenue each year. The biotechnology company earns $-65,740,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. ADMA Biologics employs 314 workers across the globe.View Additional Information About ADMA Biologics.

The official website for ADMA Biologics is http://www.admabiologics.com/.

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]